



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

02 May 2021

COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
New (1st dose)	39,169	6,655	2,048	2,336	1,486	1,435	934	486	178
New (1st dose)	7,712	691	1	1	570	463	152	118	135
Total (1st)	3,395,104	519,845	216,297	144,493	168,439	106,699	95,261	57,430	16,276
Total (2nd)	236,188	36,591	12,110	8,709	17,905	8,405	6,801	10,086	2,489
	Total	Province							
		Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam
New (1st dose)	12,148	1,041	1,320	1,649	1,592	1,500	1,253	2,589	519
New (1st dose)	3,167	444	371	146	358	0	500	451	144
Total (1st)	749,087	133,957	128,784	169,778	178,729	200,358	220,834	247,589	41,248
Total (2nd)	38,294	14,046	13,515	12,696	12,836	12,310	8,425	14,717	6,253

※ Figures subject to correction recording update

Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total	%	General ¹⁾	Anaphylaxis suspected ²⁾	Severe suspected ³⁾	Deaths
Total	New	3,631,292	328	0.46%	321	1	2	4
	Total		16,524		16,210	174	61	79
AstraZeneca	New	1,829,425	236	0.78%	234	1	0	1
	Total		14,204		13,986	140	34	44
Pfizer	New	1,801,867	92	0.13%	87	0	2	3
	Total		2,320		2,224	34	27	35

¹⁾ Mild cases such as headache, fever, nausea, vomiting, etc.

²⁾ Anaphylactoid reaction and anaphylactic shock suspected cases reported by healthcare institutions; Anaphylactoid reaction refers to occurrence of symptoms such as shortness of breath, rashes, etc. within 2 hours of vaccination and differs from anaphylaxis

³⁾ Includes convulsion and other nervous system response and ICU admitted cases

※ Based on the patient's condition at the time of initial report (general, anaphylaxis suspected, severe suspected, death)

※ Cases reported as suspected cases of AEFI; causal association not yet determined; investigation for assessment of causal association to take place for deaths or anaphylaxis cases



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

02 May 2021

Confirmed cases by gender and age group

		New cases (%)	Total cases (%)	Incidence rate* (per 100,000)
Total		606 (100)	123,240 (100)	237.70
Sex	Male	310 (51.16)	61,370 (49.80)	237.29
	Female	296 (48.84)	61,870 (50.20)	238.10
Age	80 or above	26 (4.29)	5,373 (4.36)	282.90
	70-79	34 (5.61)	8,895 (7.22)	246.60
	60-69	89 (14.69)	18,962 (15.39)	298.88
	50-59	126 (20.79)	22,815 (18.51)	263.24
	40-49	91 (15.02)	18,269 (14.82)	217.77
	30-39	99 (16.34)	16,623 (13.49)	235.95
	20-29	74 (12.21)	18,345 (14.89)	269.53
	10-19	44 (7.26)	8,622 (7.00)	174.52
0-9	23 (3.80)	5,336 (4.33)	128.62	

* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		2 (100)	1,833 (100)	1.49	170 (100)
Sex	Male	0 (0.00)	910 (49.65)	1.48	114 (67.06)
	Female	2 (100)	923 (50.35)	1.49	56 (32.94)
Age	80 or above	2 (100)	1,008 (54.99)	18.76	46 (27.06)
	70-79	0 (0.00)	523 (28.53)	5.88	64 (37.65)
	60-69	0 (0.00)	216 (11.78)	1.14	39 (22.94)
	50-59	0 (0.00)	62 (3.38)	0.27	13 (7.65)
	40-49	0 (0.00)	14 (0.76)	0.08	5 (2.94)
	30-39	0 (0.00)	7 (0.38)	0.04	2 (1.18)
	20-29	0 (0.00)	3 (0.16)	0.02	1 (0.59)
	10-19	0 (0.00)	0 (0.00)	0.00	0 (0.00)
0-9	0 (0.00)	0 (0.00)	0.00	0 (0.00)	

* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

AGE DISTRIBUTION OF SEVERE/CRITICAL CASES

	4.19.	4.20.	4.21.	4.22.	4.23.	4.24.	4.25.	4.26.	4.27.	4.28.	4.29.	4.30.	5.1	5.2.
Total	99	109	116	125	127	136	136	132	156	160	157	164	174	170

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)